Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma

NCT06012695 is registered in ClinicalTrials.gov with Novelwise Pharmaceutical Corporation as lead sponsor.

NCT NCT06012695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06012695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma
Lead sponsor
Novelwise Pharmaceutical Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 11, 2023
Completion date
September 30, 2029
Enrollment
79 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm, malignant neoplasm of brain